Latest Conference Articles

The DARE-19 clinical trial explores the use of SGLT2 inhibitors for patients with hypertension, cardiovascular disease, heart failure, type 2 diabetes, or chronic kidney disease, and COVID-19.

Study presented at the American Diabetes Association (ADA) 81st Scientific Sessions shows meaningful outcomes for people with diabetes who use the FreeStyle Libre system.

Data show diabetes patients not taking medication experienced longer hospitalization and recovery from the coronavirus.

Too much bile acids can lead to damage in the cell membranes and can cause cell death and inflammation.

Initial data show that children presented with higher acuity in 2020 compared to the previous year.

Studies show that an increased life expectancy is attributable to growth in gross domestic product, increases in the average years of school, and other social factors.

Novel treatments and recent data about new drugs were presented at the first conference of Advanced Topics for Oncology Pharmacy Professionals (ATOPP).

Improvements in glycemic control were seen as early as 3 months after program implementation and were sustained up to a year with continued program engagement.

The objective of the study was to determine the impact of telemedicine consultations in the context of the COVID-19 pandemic on the glycemic control of patients at an endocrinology clinic.

Individuals with diabetes, and other related underlying health conditions, are being hospitalized 6 times more often and are 12 times more likely to die of COVID-19 than those without diabetes.

The study examining venetoclax and obinutuzumab is in progress and currently recruiting patients who are newly diagnosed with asymptomatic, high-risk CLL.

Data were presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Conference.

Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.

Patients with prostate cancer have to be approached differently depending on the state of their metastases.

Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.

While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.

The definition of oligometastatic disease has continued to be shrouded in uncertainty due to the varying assessment criteria that exist at present during trial analyses.

Margetuximab, trastuzumab deruxtecan, and tucatinib have all been approved in the past 2 years for the treatment of various subsets of patients with breast cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what is still needed to be investigated in the future following the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what some of the most important findings were in regard to patient outcomes from the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses findings regarding adverse events during the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what the findings of the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer may mean for future treatment options.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses his presentation on surgical outcomes from the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the overall impact of the research assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.